NASDAQ OMX

IBFD and Tax Analysts Join Forces for Global Perspective on U.S. Tax Reform

Dela

U.S. tax reform is high on the agenda.  The administration of U.S. President Donald Trump recently unveiled the core principles of  "the most significant tax reform since 1986". IBFD and Tax Analysts, the top two sources of expertise on U.S. and international taxation, have pooled their resources to offer a global perspective on U.S. tax reform in a special issue of the Bulletin for International Taxation.

AMSTERDAM, June 27, 2017 (GLOBE NEWSWIRE) -- IBFD and Tax Analysts share a mission: to promote the understanding of taxation and to foster open and informed debate. As independent, non-partisan and not-for-profit organizations, they have combined their extensive coverage and analysis of U.S. domestic and cross-border taxation, in order to examine the implications of U.S. tax reform both at home and abroad.

"It appears that the U.S. is embarking on the first major review and possible changes to the U.S. tax code in decades and everyone wants to better understand it," said Christopher Bergin, CEO of Tax Analysts. "That is why we exist, to provide timely news and in-depth analysis of major tax matters such as tax reform. By partnering with IBFD, we will help taxpayers globally understand the key measures and potential impact on them." 

"The combination of a Republican president and Republican majorities in both the House of Representatives and the Senate makes the enactment of comprehensive tax reform likely," explained Jan Maarten Slagter, CEO of IBFD. "This is why, together with Tax Analysts, we have produced a special issue of the Bulletin for International Taxation. Its 27 expert articles will go a long way to help tax professionals anticipate the potential complexities of the proposed measures. This  project marks the beginning of our combined efforts to further advance our shared mission."

"With growing globalization, taxation is often at the heart of national policies, as we are now seeing in the U.S.," said Maarten Goudsmit, IBFD's Director of Publishing. "In the end, it is the taxpayer, whether as an individual or as a corporation, who must adapt to the resulting changes in their practices. IBFD and Tax Analysts share an important role in providing the affected parties with the best possible answers to their questions. Over the past months, it has been a pleasure and a privilege to work with Tax Analysts to fulfil this role."

The Special Issue for the Bulletin of International Taxation provides a comprehensive and detailed analysis of the proposed reform measures and examines their impact on inbound and outbound investment activities and cross-border trade. The articles will also be published in parallel with the Tax Analyst platform. The Special Issue seeks to provide readers with answers to the following questions:

  • Investment location: Will the tax reform increase the attractiveness of the U.S. as an investment location? How will foreign investors be affected by the reform?
  • Tax structures and business models: How will the existing tax structures need to be adapted? How will border adjustments affect international trade? What will be their impact on outsourcing and offshoring structures?
  • International response: How will other countries respond to the U.S. tax reform?
  • Simplification and compliance: Will the tax reform simplify the U.S. tax system? Will the compliance burden be reduced?

About IBFD
IBFD is a leading international provider of cross-border tax expertise, with a long-standing history of supporting and contributing to tax research and academic activities. As an independent foundation, IBFD utilizes its global network of tax experts and its Knowledge Centre to serve Fortune 500 companies, governments, international consultancy firms and tax advisors. Headquartered in Amsterdam, IBFD has regional offices in Beijing, Washington and Kuala Lumpur. IBFD's Library and Information Centre is widely regarded as the world's leading research facility in the field of international and comparative taxation.

Renowned as the leading expertise portal in the field of cross-border taxation and legislation, IBFD's powerful Tax Research Platform allows tax practitioners around the world to access a wealth of reliable and valuable content, enabling faster and more effective work.

IBFD's complete coverage further includes courses, journals and books, and a Master's in International Tax Law (in collaboration with the University of Amsterdam). IBFD also offers government consultancy and individual client research services.

About Tax Analysts
Tax Analysts is the nonpartisan, nonprofit organization that publishes Tax Notes, the leading multimedia source of breaking news, in-depth analysis, and insightful commentary on tax administration and policy. Tax Analysts has the industry's largest tax-dedicated correspondent staff, with more than 250 domestic and international correspondents. Tax Analysts provides tax news and analysis for more than 150,000 tax professionals in law and accounting firms, corporations, and government agencies worldwide, as well as academics. All rely on Tax Analysts' federal, state, and international content daily. Key products include Tax Notes Tax Notes TodayState Tax NotesState Tax TodayTax Notes International , and Worldwide Tax Daily.

About the Bulletin for International Taxation
IBFD established the Bulletin for International Taxation (BIT) in 1946. This informative and well-respected journal examines tax policy changes and tax developments throughout the world and gives background and perspective to the changes.

In the Special Issue: A Global Perspective on the US Tax Reform, authors comment on the US tax reform from the perspective of their country or region (for example, China, India, Latin America, Brazil, Europe, the Netherlands, Germany, Belgium and Singapore) and address some topical issues relevant for international investors (border adjustment tax, territorial tax system, net investment income tax and profit repatriation).

The Special Issue features an impressive number of 27 articles (15 delivered by IBFD and 12 by Tax Analysts). Many of the articles were written by renowned tax experts, such as Reuven S. Avi-Yonah, Yariv Brauner, Joachim English, Stephen Phua, Pasquale Pistone, David Rosenbloom, Christoph Spengel and Frans Vanistendael. The Special Issue also includes other contributions written by IBFD and in-house tax experts at Tax Analysts.

Contact information:
Sorrel Hidding, Head of Marketing: +31 (0) 613325049 or s.hidding@ibfd.org




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IBFD via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Hoylu AB: HOYLU HIRES NEW CTO, SATOSHI NAKAJIMA AND ANNOUNCES EXPANSION INTO JAPAN14.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 14, 2018 - Hoylu, a leading enterprise collaboration company, announced today Satoshi Nakajima will join Hoylu in the newly created position, as Chief Technology Officer and President of Hoylu Japan. Nakajima will guide the strategic technology direction and innovation of Hoylu while also leading the new Hoylu office in Tokyo, Japan. "Satoshi is a visionary and world-class technologist who has substantial experience in delivering world class innovations. He is joining the Company as we are extending our reach and expanding into Japan," said Stein Revelsby, CEO. "Satoshi's extensive experience in strategy and delivering technology that support a great user experience will make an immediate impact on the company." Nakajima will serve as President of Hoylu Japan and will report to Stein Revelsby. His leadership will strengthen customer relations and help develop new business among emerging and established Japanese companies while strengthening the global position

Hoylu AB: HOYLU ANSTÄLLER SATOSHI NAKAJIMA SOM NY CTO OCH EXPANDERAR TILL JAPAN14.9.2018 08:30Pressmeddelande

Malmö, Sverige, 14 september 2018 - Hoylu, ett ledande företag inom samarbetsmjukvara för företagsmarknaden annonserar idag att Satoshi Nakajima tar anställning som CTO (Chief Technology Officer) och President för Hoylu Japan. Nakajima kommer styra den strategiska inriktningen för företagets produkter och leda innovationsarbetet. Han kommer också leda Hoylus nyöppnade kontor i Tokyo, Japan. Satoshi är en visionär teknologiexpert som har stor erfarenhet av att skapa innovativa lösningar. Han kommer till Hoylu samtidigt som vi utökar marknaden till att även täcka in Japan säger Stein Revelsby, VD. "Satoshis långa och gedigna erfarenhet i strategiska frågor och tekniska lösningar med fokus på användarupplevelse kommer få stor betydelse för oss." Nakajima kommer även att bli President för Hoylu Japan och kommer rapportera till Stein Revelsby. Hans ledarskap kommer stärka existerande kundrelationer och utveckla nya affärer på den japanska marknaden och samtidigt bidra till att flytta fram p

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum